Key facts
- Modal Therapeutics’s last known valuation is $43.5M (Sep 2025).
- It has raised $30.0M; the latest was Seed Round ($10.0M) in Sep 2025.
- Notable investors include Foresite Capital, Arkin Capital.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Modal Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Modal Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Modal Therapeutics
Operator of a biotechnology company, dedicated to the discovery and development of targeted therapies for patients with a wide range of serious and rare diseases. The company is currently operating in a Stealth mode.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2023
- Website
- modaltx.com/
- Ownership
- Privately Held (backing)
Modal Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Modal Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Modal Therapeutics in its N-PORT filings yet. We sweep new filings monthly.